Study | Intervention | Type of trial | Patient characteristics | Outcomes |
---|---|---|---|---|
Zhen Yuan 2021 [9] | PLD 40Â mg/m2 q4wks 6 cycles | open-label, single-arm and multicenter prospective clinical trial | ovarian cancer | ORR, DCR, AEs, QOL |
ALEX 2015 [26] | PLD 40Â mg/m2 q4wks longer than 1Â year | retrospective chart clinical trial | recurrent ovarian cancer, tubal and peritoneal carcinoma | PFS, OS, Cardiac Toxicity |
Sarah E 2013 [27] | PLD 40Â mg/m2 q4wks adjustments for toxicity consisted of either dose reduction or treatment delay | retrospective chart clinical trial | recurrent or refractory ovarian cancer, or endometrial cancer, primary peritoneal cancer, and fallopian tube cancer | Cardiac Toxicity |
Joshua P 2010 [28] | PLD 30 or 40Â mg/m2 q4wks adjustments for toxicity consisted of either dose reduction or treatment delay | retrospective chart clinical trial | ovarian cancer, primary peritoneal, endometrial, fallopian, tube, cervix and vulva cancer | Cardiac Toxicity |
E. Andreopoulou 2008 [30] | PLD 30 or 40Â mg/m2 q4-8wks adjustments for toxicity consisted of either dose reduction or treatment delay | retrospective chart clinical trial | recurrent ovarian cancer, fallopian tube cancer | Cardiac Toxicity |
M. E. R. O’Brien 2004 [31] | PLD 50 mg/m2 q4wks | phase III randomized multicenter, open-label trial | women with metastatic breast cancer | PFS, OS, Cardiac Toxicity |
doxorubicin 60Â mg/m2 q3wks | ||||
Denise Uyar 2004 [32] | PLD 20 or 40 mg/m2 q4-6wks ≥ 6 cycles | retrospective chart clinical trial | ovarian cancer, primary peritoneal and endometrial cancer | Cardiac Toxicity |
Sandrine Faivre 2004 [33] | PLD 35 mg/m2 q3wks | phase I–II randomized multicenter, open-label trial | recurrent squamous cell carcinoma of the head and neck | ORR, Toxicity |
PLD 45Â mg/m2 q3wks | ||||
C.L. Kushnir 2015 [34] | PLD cumulative doses of 300 mg/m2 (range 60–1420 mg/m2) | retrospective chart clinical trial | ovarian cancer, primary peritoneal, Fallopian tube, endometrium, cervix, GYN origin, ovary and endometrium, Vaginal cancer | Cardiac Toxicity |
Keith M 2017 [35] | cumulative doxorubicin > 450 mg/m2 (free doxorubicin combined with PLD),25% patients > 1000 mg/m2 | retrospective chart clinical trial | advanced malignancies | Cardiac Toxicity |
G. Berry 1998 [36] | cumulative PLD (20 mg/m2 q2wks) of 440—840 mg/m2 | retrospective chart clinical trial | AIDS Kaposi's sarcoma | Cardiac Toxicity |
cumulative doxorubicin (20 mg/m2 q2wks) of 174–671 mg/m2 | ||||
Cardiac Toxicity 2004 [37] | cumulative doxorubicin dose of ≥ 550 mg/m2 ( including PLD) or ≥ 400 mg/m2 of PLD alone | retrospective chart clinical trial | advanced malignancies | Cardiac Toxicity |
Sarah E.2013 [38] | PLD median dose of 200Â mg/m2 (range 40 -1775Â mg/m2) | retrospective chart clinical trial | ovarian cancer, endometrial and other cancer | Cardiac Toxicity |